Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Cocrystal Pharma to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
Valuation & Earnings
This table compares Cocrystal Pharma and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cocrystal Pharma | $330,000.00 | -$8.83 million | -1.31 |
| Cocrystal Pharma Competitors | $18.55 billion | $3.23 billion | 555.14 |
Cocrystal Pharma’s peers have higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and price targets for Cocrystal Pharma and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
| Cocrystal Pharma Competitors | 7854 | 13807 | 25847 | 1040 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 29.23%. Given Cocrystal Pharma’s peers stronger consensus rating and higher probable upside, analysts clearly believe Cocrystal Pharma has less favorable growth aspects than its peers.
Institutional & Insider Ownership
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Cocrystal Pharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -295.88% | -156.05% |
| Cocrystal Pharma Competitors | -2,391.71% | -206.09% | -14.88% |
Volatility and Risk
Cocrystal Pharma has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Cocrystal Pharma’s peers have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.
Summary
Cocrystal Pharma peers beat Cocrystal Pharma on 10 of the 13 factors compared.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
